Vanguard Group Inc. Has $489.82 Million Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Vanguard Group Inc. boosted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 11.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 20,257,116 shares of the company's stock after acquiring an additional 2,020,722 shares during the quarter. Vanguard Group Inc. owned approximately 9.27% of Hims & Hers Health worth $489,817,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in HIMS. Main Management ETF Advisors LLC acquired a new position in shares of Hims & Hers Health during the 3rd quarter valued at about $672,000. Means Investment CO. Inc. boosted its position in Hims & Hers Health by 23.5% during the fourth quarter. Means Investment CO. Inc. now owns 50,040 shares of the company's stock worth $1,210,000 after purchasing an additional 9,508 shares during the period. Principal Financial Group Inc. grew its holdings in Hims & Hers Health by 102.0% during the third quarter. Principal Financial Group Inc. now owns 290,414 shares of the company's stock valued at $5,349,000 after purchasing an additional 146,621 shares during the last quarter. State of Alaska Department of Revenue bought a new position in shares of Hims & Hers Health in the fourth quarter valued at approximately $2,628,000. Finally, Pacer Advisors Inc. bought a new stake in shares of Hims & Hers Health during the 4th quarter worth $374,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Performance

NYSE HIMS traded down $2.06 during trading on Friday, reaching $25.93. 27,621,633 shares of the company traded hands, compared to its average volume of 14,730,901. The stock's 50 day moving average price is $39.82 and its two-hundred day moving average price is $30.03. Hims & Hers Health, Inc. has a 1-year low of $11.20 and a 1-year high of $72.98. The company has a market cap of $5.76 billion, a price-to-earnings ratio of 58.93 and a beta of 1.65.

Remove Ads

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Soleil Boughton sold 268,932 shares of the company's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the transaction, the insider now directly owns 169,803 shares in the company, valued at approximately $4,712,033.25. This represents a 61.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Andrew Dudum sold 128,127 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the completion of the sale, the chief executive officer now directly owns 97,687 shares of the company's stock, valued at approximately $5,692,221.49. This represents a 56.74 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,078,738 shares of company stock valued at $38,386,521. 17.71% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on HIMS. Truist Financial boosted their target price on shares of Hims & Hers Health from $24.00 to $39.00 and gave the stock a "hold" rating in a research report on Wednesday, February 26th. Citigroup reiterated a "sell" rating and set a $27.00 price target on shares of Hims & Hers Health in a report on Thursday, March 6th. Needham & Company LLC upped their target price on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a research note on Tuesday, February 25th. BTIG Research began coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They issued a "buy" rating and a $35.00 price target on the stock. Finally, Morgan Stanley downgraded shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and boosted their price objective for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $37.31.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.